Cancers display widespread RNA dysregulation, including alternative splicing of transcripts. These aberrant transcripts are often translated into cancer-specific proteins and have been shown to affect cancer initiation, progression, metastasis, and drug resistance. While it has been recently reported that cancer-specific isoforms can be used as novel prognostic biomarkers and serve as an untapped source of drug targets for immuno-oncology, the vast majority of cancer specific isoforms remain unknown. With at least 95% of genes undergoing alternative splicing and producing multiple isoforms, much remains to be discovered.
Watch the recording to learn:
The roles of RNA isoforms in cancer biology
How long-read RNA sequencing can help you uncover the molecular heterogeneity of cancers
Why the Iso-Seq method is the best way to identify RNA isoforms in cancer
Register to watch recording
Olga Anczukow, PhD Revealing alternative splicing alterations in breast cancer using long-read RNA sequencing
Associate Professor The Jackson Laboratory
Elizabeth Tseng, PhD Q&A panelist Associate Director, Product Marketing PacBio
Jonathan Bibliowicz, PhD Host and moderator
Associate Director, Cancer Research PacBio
Democratizing Genome Assembly and Annotation
Ted Kalbfleisch, Ph.D., Associate Professor, University of Kentucky
Molecular Genetic Applications Enabled by Platinum Quality Reference Genome Assemblies in Octoploid Strawberry
Mitchell Feldmann, Ph.D., Postdoctoral Fellow, University of California, Davis.